PRLD

Prelude Therapeutics Incorporated

3.90 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Prelude Therapeutics Incorporated stock is down -2.5% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 June’s closed higher than May.

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.